Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

Only thing that matters is FINANCING & DILUTION!

ENDV will not be able to do anything without being able to finance its operations, which it cannot do at the moment. Because the toxic lenders they have been using to raise capital can no longer convert their debt into freely traded shares, ENDV can no longer find adequate
financing to even fund its regulatory filings let alone develop any new products.

Dilution has always and will always be a big problem with these penny stocks. The company continues to print new shares at an alarming rate, both to keep the toxic lenders from throwing the company into bankruptcy, but also to personally enrich its management and BOD. Nobody wants to be stuck holding the bag, so volume only rises after the stock crashes and a new set of speculators moves in to then pump and dump the stock all over again.